Here's Why Viking Therapeutics Shares Slumped Today
It's been an eventful week for the weight-loss drug company, which continues to impress with its clinical data, and today's move isn't much to worry about.
Viking Therapeutics (NASDAQ: VKTX) shares experienced a significant drop of 14.5% in early trading on Monday, following the company's announcement of the results from a maintenance study of its key weight-loss drug, VK2735. Despite the initial decline, the results were promising and led management to announce a new offering of common stock and convertible senior notes.
The company raised an additional $200 million through the sale of these securities, which were initially priced at $35 per share and $225 million in convertible senior notes due in 2023. The increased offering was met with positive market response, prompting Viking Therapeutics to expand the offering to 7,857,143 shares at $35 each and $225 million in convertible senior notes.
It is important to note that today's share price decline is not directly linked to the positive results released two days ago.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
